AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25992505 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding (40 to 60% of calculated caloric requirements)
Number of subjects: 894
Study 25992505 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral feeding (70 to 100% of calculated caloric requirements)
Number of subjects: 894
Study 25992505 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 894
Study 25992505 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral feeding
Number of subjects: 894
Study 23602862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of 25(OH)D concentrations
Number of subjects: 4233
Study 23602862 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations
Number of subjects: 4233
Study 21911632 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 703
Study 21911632 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 703
Study 19735542 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Medicine (IM) care with seven treatment sessions from two different types of complementary therapies over ten weeks.
Number of subjects: 80
Study 19735542 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Medicine (IM) care
Number of subjects: 80
Study 19735542 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (advice and prescription of analgesics)
Number of subjects: 80
Study 16434256 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 32
Study 16434256 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 32
Study 16434256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 15133637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration biopsy (FNA)
Number of subjects: 130
Study 15133637 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBI scans
Number of subjects: 130
Study 15133637 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen section biopsy (FS)
Number of subjects: 130
Study 15133637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of FNA, MIBI, and FS
Number of subjects: 130
Study 11600538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient endogenous GH
Number of subjects: 250
Study 11600538 — intervention group
Group type: COMPARATOR
Intervention: GH deficiency
Number of subjects: 250
Study 11600538 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy adolescents (both boys and girls)
Number of subjects: 250
Study 11600538 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy adolescents (ages 17-21)
Number of subjects: 250
Study 9028311 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with fractionated total body irradiation, etoposide (VP) 60 mg/kg, and cyclophosphamide (Cy) 100 mg/kg.
Number of subjects: 119
Study 9028311 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with BCNU 15 mg/kg, VP 60 mg/kg, and Cy 100 mg/kg.
Number of subjects: 119
Study 9028311 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with CCNU 15 mg/kg, VP 60 mg/kg, and Cy 100 mg/kg.
Number of subjects: 119
Study 9028311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with none of the unfavorable prognostic factors (systemic symptoms at relapse, disseminated pulmonary or bone marrow disease at relapse, and more than minimal disease at the time of transplantation).
Number of subjects: 119
Study 9028311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with one or more unfavorable prognostic factors.
Number of subjects: 119
Study 8330870 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (Sandostatin, Sandoz, Switzerland)
Number of subjects: 10
Study 8330870 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM 23014 (Lanreotide, Ipsen Biotech, France)
Number of subjects: 10
Study 2438451 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-molecular weight hydroxyethyl starch
Number of subjects: 0
Study 2438451 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular weight dextran solution
Number of subjects: 0
Study 31298289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perineural PRP injection and medical treatment
Number of subjects: 60
Study 31298289 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 60
Study 28786698 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Number of subjects: 0
Study 27298527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine 2% lignocaine
Number of subjects: 84
Study 27298527 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 84
Study 26654906 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial cell preparation (daily dosage of 6 × 10^10 CFU)
Number of subjects: 136
Study 26654906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 23532097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI)
Number of subjects: 692
Study 23532097 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir (RTV)
Number of subjects: 692
Study 20950389 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity stepped care intervention aimed at reducing depressive symptoms
Number of subjects: 114
Study 20950389 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 114
Study 18227766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpenetrating very deep sclerectomy (NPVDS) with reticulated hyaluronic acid implant (SKGEL)
Number of subjects: 50
Study 18227766 — intervention group
Group type: COMPARATOR
Intervention: Nonpenetrating deep sclerectomy (NPDS)
Number of subjects: 50
Study 16595356 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention for T‐ACE positive women
Number of subjects: 51
Study 16595356 — intervention group
Group type: COMPARATOR
Intervention: T‐ACE negative group
Number of subjects: 51
Study 16595356 — intervention group
Group type: COMPARATOR
Intervention: T‐ACE positive group
Number of subjects: 51
Study 15374551 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT cuff inflated to achieve sealing pressure (Pseal group)
Number of subjects: 50
Study 15374551 — intervention group
Group type: COMPARATOR
Intervention: ETT cuff inflated to achieve a pressure of 25 cm H2O (P25 group)
Number of subjects: 50
Study 11298610 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg/kg/d intravenous (i.v.) anti-D
Number of subjects: 27
Study 11298610 — intervention group
Group type: COMPARATOR
Intervention: 50 microg/kg/d intravenous (i.v.) anti-D
Number of subjects: 27
Study 9253562 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 75 micrograms kg‐1
Number of subjects: 160
Study 9253562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg kg‐1
Number of subjects: 160
Study 9253562 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 75 micrograms kg‐1 and Ondansetron 0.1 mg kg‐1
Number of subjects: 160
Study 9253562 — intervention group
Group type: COMPARATOR
Intervention: NaCl as placebo
Number of subjects: 160
Study 8310137 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal pelvic radiotherapy (dose levels of 30‐38 Gy)
Number of subjects: 0
Study 8310137 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal pelvic radiotherapy (dose levels of 56‐65 Gy)
Number of subjects: 0
Study 8310137 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal pelvic radiotherapy (general assessment)
Number of subjects: 0
Study 3538914 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 15
Study 3538914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31575508 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg every 8 weeks
Number of subjects: 3910
Study 31575508 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks
Number of subjects: 3910
Study 31575508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3910
Study 31234547 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention providing advice on work-recovery-rest balance, food and drink intake, and physical activity.
Number of subjects: 96
Study 31234547 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 96
Study 31234547 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study 28097317 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus 6 months of androgen deprivation therapy
Number of subjects: 157
Study 28097317 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 157
Study 26085515 — intervention group
Group type: EXPERIMENTAL
Intervention: HSF + DHA diet (3.45 g DHA/d and 0.5 g EPA/d)
Number of subjects: 82
Study 26085515 — intervention group
Group type: COMPARATOR
Intervention: HSF diet
Number of subjects: 82
Study 23663917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored regimen (daily pills until three consecutive days bleeding triggers a 3‐day pill‐free interval) of Microgynon 30® (ethinyl oestradiol 30 mcg, levonorgestrel 150 mcg)
Number of subjects: 503
Study 23663917 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (21 daily pills followed by a 7‐day pill‐free interval) of Microgynon 30® (ethinyl oestradiol 30 mcg, levonorgestrel 150 mcg)
Number of subjects: 503
Study 23663917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored regimen
Number of subjects: 503
Study 23663917 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 503
Study 21856336 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodic tDCS (20 min, 1 mA) during intensive language training
Number of subjects: 3
Study 21856336 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation during intensive language training
Number of subjects: 3
Study 20415935 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen arginate (PRE group)
Number of subjects: 30
Study 20415935 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen arginate (POST group)
Number of subjects: 30
Study 17847722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy
Number of subjects: 32
Study 17847722 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 32
Study 15197379 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task workers providing feeding assistance during mealtimes
Number of subjects: 0
Study 11700188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue coblation
Number of subjects: 38
Study 11700188 — intervention group
Group type: COMPARATOR
Intervention: Standard bipolar dissection
Number of subjects: 38
Study 9207618 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day)
Number of subjects: 92
Study 9207618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 8424190 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction curettage
Number of subjects: 357
Study 8424190 — intervention group
Group type: COMPARATOR
Intervention: Conventional curettage
Number of subjects: 357
Study 3469225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick plain wire bonded only to the canines
Number of subjects: 44
Study 3469225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick twisted wire bonded only to the canines
Number of subjects: 44
Study 3469225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin twisted wire bonded to each tooth
Number of subjects: 44
Study 3469225 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable retainers
Number of subjects: 44
Study 3469225 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 44
Study 30655097 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter watching
Number of subjects: 86
Study 30655097 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter left the room
Number of subjects: 86
Study 30655097 — intervention group
Group type: COMPARATOR
Intervention: Experimenter turned away
Number of subjects: 86
Study 30655097 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel boxes
Number of subjects: 86
Study 30655097 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar boxes
Number of subjects: 86
Study 27502287 — intervention group
Group type: EXPERIMENTAL
Intervention: DCV-TRIO for 12 weeks
Number of subjects: 217
Study 27502287 — intervention group
Group type: COMPARATOR
Intervention: DUAL for 24 weeks
Number of subjects: 217
Study 27502287 — intervention group
Group type: EXPERIMENTAL
Intervention: DCV-TRIO
Number of subjects: 217
Study 27502287 — intervention group
Group type: COMPARATOR
Intervention: DUAL
Number of subjects: 217
Study 26255087 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural (n = 80)
Number of subjects: 159
Study 26255087 — intervention group
Group type: COMPARATOR
Intervention: HRT (n = 79)
Number of subjects: 159
Study 23088552 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free chlorhexidine (CHX; Paroex)
Number of subjects: 20
Study 23088552 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils (EO; Listerine)
Number of subjects: 20
Study 23088552 — intervention group
Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 20
Study 21700944 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmin
Number of subjects: 15
Study 21700944 — intervention group
Group type: COMPARATOR
Intervention: rtPA
Number of subjects: 15
Study 19433378 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based informational campaign
Number of subjects: 0
Study 19433378 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of the campaign and a cognitive-behavioral small group intervention
Number of subjects: 0
Study 19433378 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (participants from a second college campus)
Number of subjects: 0
Study 16426317 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction
Number of subjects: 88
Study 16426317 — intervention group
Group type: COMPARATOR
Intervention: Antithymocyte globulin induction
Number of subjects: 88
Study 14983952 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with transrectal ultrasonography (TRUS) and sextant prostate biopsy when PSA >4 ng/mL (or >2.9 ng/mL after May 1998)
Number of subjects: 4278
Study 14983952 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recall attendance after initial screening
Number of subjects: 4278
Study 14983952 — intervention group
Group type: EXPERIMENTAL
Intervention: Second screening round
Number of subjects: 4278
Study 14983952 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diagnostic tests)
Number of subjects: 4278
Study 14983952 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 4278
Study 10919682 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg four times daily via HFA 134a pMDI (Ventolin CFC-free)
Number of subjects: 547
Study 10919682 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 microg four times daily via CFC pMDI (Ventolin)
Number of subjects: 547
Study 8639796 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Formulation (WF) - intermediate/high-grade
Number of subjects: 670
Study 8639796 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Formulation (WF) - low-grade
Number of subjects: 670
Study 8639796 — intervention group
Group type: EXPERIMENTAL
Intervention: MCL
Number of subjects: 670
Study 8639796 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle center cell lymphomas
Number of subjects: 670
Study 8639796 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse large B-cell lymphomas
Number of subjects: 670
Study 1601560 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-meter shuttle run test (20-MST)
Number of subjects: 11
Study 1601560 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Montreal track test (UM-TT)
Number of subjects: 11
Study 1601560 — intervention group
Group type: COMPARATOR
Intervention: Laboratory treadmill test
Number of subjects: 11
Study 2864847 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 110
Study 2864847 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 110
Study 30673755 — intervention group
Group type: COMPARATOR
Intervention: Peri-urban residents
Number of subjects: 671
Study 30673755 — intervention group
Group type: COMPARATOR
Intervention: Rural Highland residents
Number of subjects: 671
Study 29345992 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation-enhanced case management for 12 months
Number of subjects: 270
Study 29345992 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorder treatment in jail
Number of subjects: 270
Study 29345992 — intervention group
Group type: COMPARATOR
Intervention: Latino individuals
Number of subjects: 270
Study 27650051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular betamethasone (11.4 mg Celestone Chronodose), repeated weekly if risk of very preterm birth remained
Number of subjects: 963
Study 27650051 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo, repeated weekly if risk of very preterm birth remained
Number of subjects: 963
Study 27650051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular betamethasone (11.4 mg Celestone Chronodose)
Number of subjects: 963
Study 27650051 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 963
Study 25024623 — intervention group
Group type: EXPERIMENTAL
Intervention: BM‐MNCs transplantation plus routine medical treatment
Number of subjects: 47
Study 25024623 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only (Control)
Number of subjects: 47
Study 22351510 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive response-outcome contingencies (Experiment 1)
Number of subjects: 0
Study 22351510 — intervention group
Group type: EXPERIMENTAL
Intervention: Some outcomes not contingent on participants' responses (Experiment 2)
Number of subjects: 0
Study 22351510 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative response-outcome contingency with manipulated performance expectancies (Experiment 3)
Number of subjects: 0
Study 22351510 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized ratings to novel stimuli through derived relations (all experiments)
Number of subjects: 0
Study 20552089 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic resin specimens
Number of subjects: 21
Study 20552089 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture liner specimens
Number of subjects: 21
Study 18347544 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL/MMF
Number of subjects: 51
Study 18347544 — intervention group
Group type: COMPARATOR
Intervention: TAC/MMF
Number of subjects: 51
Study 16094217 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV (1 dose)
Number of subjects: 480
Study 16094217 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV (2 doses)
Number of subjects: 480
Study 16094217 — intervention group
Group type: COMPARATOR
Intervention: M‐M‐RII and VARIVAX (1 dose)
Number of subjects: 480
Study 12477671 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron i.v.
Number of subjects: 387
Study 12477671 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg metoclopramide i.v.
Number of subjects: 387
Study 12477671 — intervention group
Group type: COMPARATOR
Intervention: Saline as placebo i.v.
Number of subjects: 387
Study 10652047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (0.5 mg/kg) administered at the time of transplantation and again one month later
Number of subjects: 26
Study 10652047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9037847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg daily)
Number of subjects: 33
Study 9037847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 1370735 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aprotinin infusion (0.1‐0.4 Mill. KIU/hr)
Number of subjects: 23
Study 1370735 — intervention group
Group type: COMPARATOR
Intervention: Bolus aprotinin (0.5 Mill. KIU on three occasions)
Number of subjects: 23
Study 1370735 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aprotinin infusion
Number of subjects: 23
Study 1370735 — intervention group
Group type: COMPARATOR
Intervention: Bolus aprotinin
Number of subjects: 23
Study 6380717 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of radiotherapy and local external hyperthermia
Number of subjects: 77
Study 6380717 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 77
Study 6380717 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate combination of heat and large radiation fractions
Number of subjects: 77
Study 6380717 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval of 4 hr between heat and radiation
Number of subjects: 77
Study 6380717 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest hyperthermic treatment and largest radiation fractions
Number of subjects: 77
Study 30026282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia for 24 hours
Number of subjects: 40
Study 30026282 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 30026282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia
Number of subjects: 40
Study 29241357 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (1000 mg/day)
Number of subjects: 88
Study 29241357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 26355193 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive emotion training with musical engagement
Number of subjects: 15
Study 26355193 — intervention group
Group type: COMPARATOR
Intervention: Interactive emotion training without musical engagement
Number of subjects: 15
Study 24667140 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% normoxic VO(2)peak performed in a normoxic environment (NI-NE)
Number of subjects: 11